Rosiglitazone Reduces Incidence Of Type 2 Diabetes: Ramipril fares worse in DREAM trial.

COPENHAGEN — Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial provide further confirmation that glucose-lowering agents can delay the onset of type 2 diabetes in high-risk individuals.